Perspective Therapeutics (NYSE:CATX) Now Covered by HC Wainwright

HC Wainwright assumed coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research report issued to clients and investors on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 275.94% from the company’s current price.

Other analysts have also issued research reports about the company. Oppenheimer reduced their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Friday, January 24th. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, January 14th. Finally, Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Monday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.56.

Perspective Therapeutics Stock Performance

CATX opened at $2.66 on Thursday. The stock has a fifty day moving average of $3.17 and a 200-day moving average of $7.44. Perspective Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of the business. FMR LLC increased its position in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares during the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after purchasing an additional 120,991 shares during the last quarter. Octagon Capital Advisors LP grew its position in shares of Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Finally, State Street Corp grew its position in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.